Kaur A, Vaccari M
Viruses. 2024; 16(3).
PMID: 38543734
PMC: 10974975.
DOI: 10.3390/v16030368.
Yamamoto J, Edison L, Rowe-Haas D, Takano T, Gilor C, Crews C
Viruses. 2023; 15(4).
PMID: 37112894
PMC: 10146663.
DOI: 10.3390/v15040914.
Sadraeian M, Zhang L, Aavani F, Biazar E, Jin D
eLight. 2022; 2(1):18.
PMID: 36187558
PMC: 9510523.
DOI: 10.1186/s43593-022-00029-9.
Frenkel L, Kuller L, Beck I, Tsai C, Joy J, Mulvania T
PLoS One. 2021; 16(4):e0240495.
PMID: 33914754
PMC: 8084236.
DOI: 10.1371/journal.pone.0240495.
Burnie J, Guzzo C
Viruses. 2019; 11(1).
PMID: 30669528
PMC: 6356245.
DOI: 10.3390/v11010085.
Survivors Remorse: antibody-mediated protection against HIV-1.
Lewis G, Pazgier M, DeVico A
Immunol Rev. 2017; 275(1):271-284.
PMID: 28133809
PMC: 5642910.
DOI: 10.1111/imr.12510.
First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.
Choi E, Michalski C, Choo S, Kim G, Banasikowska E, Lee S
Retrovirology. 2016; 13(1):82.
PMID: 27894306
PMC: 5126836.
DOI: 10.1186/s12977-016-0317-2.
HIV-1 prophylactic vaccines: state of the art.
Lelievre J, Levy Y
J Virus Erad. 2016; 2(1):5-11.
PMID: 27482428
PMC: 4946697.
Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III.
Fan Y, Chiu H, Chen L, Chang G, Chiou S
PLoS Negl Trop Dis. 2015; 9(10):e0004167.
PMID: 26495991
PMC: 4619746.
DOI: 10.1371/journal.pntd.0004167.
Application of radiation technology in vaccines development.
Seo H
Clin Exp Vaccine Res. 2015; 4(2):145-58.
PMID: 26273573
PMC: 4524899.
DOI: 10.7774/cevr.2015.4.2.145.
HIV vaccine research: the challenge and the way forward.
Wang H, Mo Q, Yang Z
J Immunol Res. 2015; 2015:503978.
PMID: 25861656
PMC: 4377490.
DOI: 10.1155/2015/503978.
Microdevices for examining immunological responses of single cells to HIV.
Choi J, Jeong Y, Han H, Lee K
Biosci Rep. 2014; 34(4).
PMID: 25028990
PMC: 4137800.
DOI: 10.1042/BSR20140097.
Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDS.
Page M, Quartey-Papafio R, Robinson M, Hassall M, Cranage M, Stott J
PLoS One. 2014; 9(2):e88735.
PMID: 24551145
PMC: 3925162.
DOI: 10.1371/journal.pone.0088735.
Human immunodeficiency virus vaccine an update.
Beena V, Choudhary K, Rajeev R, Sivakumar R, Heera R, Padmakumar S
J Oral Maxillofac Pathol. 2013; 17(1):76-81.
PMID: 23798835
PMC: 3687194.
DOI: 10.4103/0973-029X.110741.
Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.
Lifson J, Haigwood N
Cold Spring Harb Perspect Med. 2012; 2(6):a007310.
PMID: 22675663
PMC: 3367532.
DOI: 10.1101/cshperspect.a007310.
The role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaques.
Wang Y, Whittall T, Rahman D, Bunnik E, Vaughan R, Scholler J
PLoS One. 2012; 7(4):e34433.
PMID: 22514633
PMC: 3326050.
DOI: 10.1371/journal.pone.0034433.
Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.
Brown S, Surman S, Sealy R, Jones B, Slobod K, Branum K
Viruses. 2010; 2(2):435-467.
PMID: 20407589
PMC: 2855973.
DOI: 10.3390/v2020435.
AIDS vaccine development: the past, the present, and the future.
Ahn S, Sung Y
Immune Netw. 2010; 9(1):1-3.
PMID: 20107530
PMC: 2803297.
DOI: 10.4110/in.2009.9.1.1.
Inactivation of respiratory syncytial virus by zinc finger reactive compounds.
Boukhvalova M, Prince G, Blanco J
Virol J. 2010; 7:20.
PMID: 20102602
PMC: 2823672.
DOI: 10.1186/1743-422X-7-20.
Cytoskeletal proteins bound to heat-shock protein 70 may elicit resistance to simian immunodeficiency virus infection of CD4(+) T cells.
Bergmeier L, Babaahmady K, Pido-Lopez J, Heesom K, Kelly C, Lehner T
Immunology. 2009; 129(4):506-15.
PMID: 20002211
PMC: 2842497.
DOI: 10.1111/j.1365-2567.2009.03202.x.